Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yohei Otake
Institution:
Eisai (Japan)
Observed institutions:
National Cancer Center Hospital,
Eisai (Japan)
ORCID:
0000-0001-5056-403X
Observed ORCID:
0000-0001-5056-403X
OpenAlex ID:
A5075434012
Safety and efficacy of MORAb-202 in patients (pts) with platinum-resistant ovarian cancer (PROC): Results from the expansion part of a phase 1 trial.
2022
·
Shin Nishio
, Mayu Yunokawa
, et al.
·
Journal of Clinical Oncology
·
21
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort
2024
·
Makoto Nishio
, Shuji Murakami
, et al.
·
Cancer Research Communications
·
5
PDF
Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results
2025
·
Kan Yonemori
, Mayu Yunokawa
, et al.
·
International Journal of Gynecology & Obstetrics
·
4
PDF
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
2024
·
Akihito Kawazoe
, Noboru Yamamoto
, et al.
·
Clinical Cancer Research
·
4
PDF
Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib
2023
·
Hanae Ida
, Toshio Shimizu
, et al.
·
Cancer Research Communications
·
4
PDF
Phase Ib trial of tasurgratinib (E7090) with or without endocrine therapies for patients (pts) with ER+, HER2− recurrent/metastatic breast cancer (BC) after receiving a CDK4/6 inhibitor.
2024
·
Takahiro Kogawa
, Toshinari Yamashita
, et al.
·
Journal of Clinical Oncology
·
3
A phase II, multicenter, single-arm trial of eribulin in patients with bevacizumab-resistant recurrent glioblastoma.
2022
·
Masamichi Takahashi
, Satoshi Kawashima
, et al.
·
Journal of Clinical Oncology
·
3
Phase 2 small cell lung cancer (SCLC) cohort of a phase 1b/2 trial of a liposomal formulation of eribulin in combination with nivolumab.
2023
·
Koichi Azuma
, Shuji Murakami
, et al.
·
Journal of Clinical Oncology
·
2
2022-RA-680-ESGO Safety and efficacy of MORAb-202 in patients with platinum-resistant ovarian cancer: results from the expansion part of a phase 1 trial in Japan
2022
·
Shin Nishio
, Mayu Yunokawa
, et al.
·
International Journal of Gynecological Cancer
·
2
PDF
Dose optimization for MORAb-202, an antibody-drug conjugate (ADC) highly selective for folate receptor-alpha (FRα), using population pharmacokinetic (PPK) and exposure-response (E-R) efficacy and safety analyses.
2022
·
Seiichi Hayato
, Lora Hamuro
, et al.
·
Journal of Clinical Oncology
·
2
Safety and Antitumor Activity of Farletuzumab Ecteribulin in Patients With NSCLC: Phase I Expansion Results
2026
·
Tatsuya Yoshida
, Toshiyuki Kozuki
, et al.
·
JTO Clinical and Research Reports
·
1
PDF
Abstract P4-10-18: Potential predictive biomarkers for a fibroblast growth factor receptor (FGFR) inhibitor: Phase 1b trial of tasurgratinib (E7090) with endocrine therapies (ET) for ER+, HER2+ recurrent/metastatic breast cancer (BC) resistant to CDK4/6 inhibitors
2025
·
Takahiro Kogawa
, Takanori Ishida
, et al.
·
Clinical Cancer Research
·
1
Effects of Food, Gastric Acid Reduction, and Strong CYP3A Induction on the Pharmacokinetics of Tasurgratinib, a Novel Selective Fibroblast Growth Factor Receptor Inhibitor
2024
·
Maiko Nomoto
, Tomoko Hasunuma
, et al.
·
The Journal of Clinical Pharmacology
·
1
PDF
E7389-LF as a first-line chemotherapy for patients with metastatic/advanced HER2-negative breast cancer: results from the phase 1 dose-expansion part of study 114
2026
·
Hiroshi Ishiguro
, Yasuo Miyoshi
, et al.
·
Breast Cancer Research
PDF
Phase 1b/2 study of the liposomal formulation of eribulin (E7389-LF) in combination with nivolumab: Results from the phase 2 esophageal cancer cohort
2024
·
Takashi Oshima
, Sachiko Yamamoto
, et al.
·
BJC Reports
PDF
Supplementary Table S4 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
2024
·
Akihito Kawazoe
, Noboru Yamamoto
, et al.
Supplementary Figure S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
2024
·
Akihito Kawazoe
, Noboru Yamamoto
, et al.
PDF
Supplementary Table S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
2024
·
Akihito Kawazoe
, Noboru Yamamoto
, et al.
Data from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
2024
·
Akihito Kawazoe
, Noboru Yamamoto
, et al.
Supplementary Figure S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
2024
·
Akihito Kawazoe
, Noboru Yamamoto
, et al.
PDF
Supplementary Table S5 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
2024
·
Akihito Kawazoe
, Noboru Yamamoto
, et al.
PDF
Supplementary Table S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
2024
·
Akihito Kawazoe
, Noboru Yamamoto
, et al.
PDF
Supplementary Figure S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
2024
·
Akihito Kawazoe
, Noboru Yamamoto
, et al.
Data from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
2024
·
Akihito Kawazoe
, Noboru Yamamoto
, et al.
Supplementary Table S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
2024
·
Akihito Kawazoe
, Noboru Yamamoto
, et al.
Show more works
View as search
Works count:
84
Citation count:
53
H-index:
4
I10-index:
1
Year
Topic
Type